Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy.
Electrochemotherapy (ECT) is a therapeutical procedure based on the induction of cell membrane electroporation, by cell exposure to electric fields lasting a few microseconds, combined with the local or systemic administration of cytotoxic drugs, with an intracellular target and high intrinsic efficacy, but poor cell membrane permeability. ECT is an effective local therapy for any histological tumour that has been used clinically since 2005 and is currently in use in 83 centres all over Europe. In the literature, ECT as a local oncological treatment shows an objective response between 70 and 90% in mucocutaneous primary and metastatic lesions, is cost effective and has few local and systemic side effects. In this manuscript, we present an overview of the European experience in ECT, as well as our own experience in a specialised Spanish oncological centre and in a basic oncological unit in Nicaragua. The purpose is to reflect on the role that this procedure could have in the treatment of skin and mucosal cancer as part of a multidisciplinary approach.
Plataforma de Oncología Fundación Tedeca, Hospital USP San Jaime, Torrevieja, Alicante, Spain.
Vicente
V
Muñoz Madero
Gloria
G
Ortega Pérez
D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D003131:Combined Modality Therapy / Q000145:classification* / Q000379:methods / Q000639:trends*; D053672:Electrochemotherapy / Q000145:classification / Q000379:methods*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
Biochem Biophys Res Commun. 1993 Jul 15;194(1):333-7
7687434
Anticancer Drugs. 2005 Mar;16(3):345-8
15711188
Melanoma Res. 2005 Feb;15(1):45-51
15714120
Cancer. 1996 Mar 1;77(5):964-71
8608491
J Am Acad Dermatol. 1996 Jan;34(1):82-6
8543699
Arch Med Res. 2001 Jul-Aug;32(4):273-6
11440782
Clin Cancer Res. 2000 Mar;6(3):863-7
10741708
Biochem Pharmacol. 1988 Dec 15;37(24):4727-33
2462423
Eur J Cancer. 2009 Jan;45(2):228-47
19097774
Br J Dermatol. 2002 Jul;147(1):62-70
12100186
Eur J Cancer. 1998 Jul;34(8):1213-8
9849482
Ann Surg Oncol. 2008 Aug;15(8):2215-22
18498012
Melanoma Res. 2000 Dec;10(6):585-9
11198481
World J Gastroenterol. 2005 Apr 28;11(16):2426-30
15832412
Biochem Pharmacol. 1999 Jan 1;57(1):45-56
9920284
Dermatol Surg. 2008 Jun;34(6):839-42; discussion 842-3
18384620
J Eur Acad Dermatol Venereol. 2010 Feb;24(2):239-41
19778362
Biochim Biophys Acta. 2002 Jan 15;1569(1-3):51-8
11853957
Melanoma Res. 2000 Oct;10(5):468-74
11095408
Tumori. 2009 May-Jun;95(3):398-402
19688986
Arch Dermatol. 2008 Sep;144(9):1186-8
18794464
Eur J Surg Oncol. 2008 Feb;34(2):232-40
17614247
J Membr Biol. 1972 Dec 29;10(3):279-90
4667921
Clin Oncol (R Coll Radiol). 2003 Feb;15(1):25-31
12602551
Cancer. 1998 Jul 1;83(1):148-57
9655305
Br J Cancer. 1998 Jun;77(12):2336-42
9649155
Br J Cancer. 2008 Jan 29;98(2):388-98
18182988
Nature. 1977 Aug 4;268(5619):438-41
895849
Ther Clin Risk Manag. 2008 Apr;4(2):541-8
18728828
J Urol. 1998 Oct;160(4):1426
9751373
C R Acad Sci III. 1991;313(13):613-8
1723647
J Cutan Med Surg. 2006 May-Jun;10(3):115-21
17241586
Exp Cell Res. 1988 Mar;175(1):15-25
3345798